CONTENTS:

This year’s 65th American Society of Hematology (ASH) Annual Meeting and Exposition was held in beautiful San Diego, California. Held December 9-12, 2023, the meeting attracted more than 30,000 clinicians, researchers, pharmaceutical company personnel and nonprofit organizations worldwide to share ground-breaking research in the field of hematology.

In this issue of the e-news, we will report on research presented in poster format at ASH that the PDSA staff and medical advisors were part of showcasing advanced knowledge on the patient experience and their quality of life living with ITP. Watch for additional ASH reports in the 2023 winter issue of The Platelet News, the PDSA quarterly newsletter.

• Binary Gender Differences in Quality of Life and Social Supports Among Individuals with Immune Thrombocytopenia (ITP): Data from the ITP Natural History Study Registry
• The Lack of Tolerable Treatments Options That Can Induce Durable Responses without Fear of Relapse after Discontinuation: Results from the ITP World Impact Survey (I-WISh) 2.0

CONTENTS:

• Trends in Outcomes and Racial Disparities in Adults with ITP
• Long-Term Use of Eltrombopag in Children with ITP

CONTENTS:

• Mycophenolate Mofetil Use in Pediatric ITP Refractory to First line Therapy
• Risk of Blood Clots in ITP Patients Treated with TPO-RAs

CONTENTS:

• Evaluating the Efficacy and Safety of Avatrombopag Vs. Eltrombopag in ITP
• Trends in Incidence and Prevalence of ITP Over Time

CONTENTS:

• Combining TPO-RAs with Immunosuppressive Medication in Adults with Refractory ITP
• Early Initiation of Second-Line Therapy in ITP

Each month, PDSA highlights research and clinical advances being made to better understand ITP and how to treat patients more effectively. In this issue, we share two presentations given at this year’s annual International Society on Thrombosis and Haemostasis (ISTH) Congress that was held in Montreal, Canada in June, and attended by PDSA staff and medical advisors.

CONTENTS:

• Clinical Evidence of Persistent Isolated Mild Thrombocytopenia (PIMT)
• The Role of Megakaryocyte Impairment In ITP

Each month, PDSA highlights clinical advances being made to better understand ITP and provide expert care to patients. In this issue, we share current research about ITP presented at the European Hematology Association (EHA) Congress held in June. PDSA staff and medical advisors are proud to be authors on both research studies.

CONTENTS:

• Nighttime Symptoms are Associated with Fatigue in Children and Adolescents with Chronic ITP
• Patient and Physician Perceptions of the Burden of ITP and its Management: Results from I-WISh 2.0

CONTENTS:

• (Phase 3) Clinical Trial Data of Avatrombopag for the Treatment of Adults with Immune Thrombocytopenia
• Using an ITP Quality Improvement Tool to Improve Adherence to Treatment Guidelines

CONTENTS:

• Immune Thrombocytopenia in Infants Compared to Toddlers
• Defining Refractory Immune Thrombocytopenia in the Pediatric Population

CONTENTS:

• Relationship Between Platelet Autoantibodies and Response to Corticosteroid Treatment in Adult Patients with Primary ITP
• IFNG-AS1 and GAS5 as Potential Molecular Indicators for Childhood ITP

CONTENTS:

PDSA’s exhibit booth at the 2022 ASH meeting in New Orleans.
(left-right: Melissa Hilsabeck, Peter Pruitt, Ken Kruse, Caroline Kruse, Jennifer DiRaimo, and Barbara Pruitt)

This year’s 64th American Society of Hematology (ASH) Annual Meeting and Exposition was held as a hybrid in-person and virtual event in New Orleans, LA, December 10-13, 2022. The meeting attracted more than 25,000 thousand clinicians, researchers, and health-care stakeholders, including the team from PDSA, to share ground-breaking research in the field of hematology. In this edition of the e-news, we report on two abstracts presented at the ASH meeting, showcasing new insights into immune thrombocytopenia (ITP).

• Cerebral Microbleeds in Children with ITP
• A Low Platelet Count in Older Adults and The Risk for a Blood Cancer

CONTENTS:

The 64th American Society of Hematology (ASH) Annual Meeting and Exposition was held as a hybrid event in New Orleans, Louisiana, December 10-13, 2022. As usual, the meeting attracted thousands of clinicians, scientists, industry partners, and even investment analysts worldwide to share ground-breaking research in the field of hematology. Here are two of the abstracts presented at ASH. Look for additional summaries of research presented at ASH in our next edition of The Platelet News, available to all PDSA members.

• Efgartigimod Treatment in Adults with Primary Immune Thrombocytopenia
• The Relationship Between Immune Thrombocytopenia (ITP) Outcome and Obesity